NCT04255368

Brief Summary

The purpose of this research is to determine the production of trimethylamine-N-oxide (TMAO) from different forms of choline and whether this response is modified by the gut microbiota composition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 9, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 16, 2018

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

January 22, 2020

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 5, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 25, 2020

Completed
Last Updated

November 4, 2020

Status Verified

November 1, 2020

Enrollment Period

7 months

First QC Date

January 22, 2020

Last Update Submit

November 3, 2020

Conditions

Keywords

Dietary precursorMetabolismGut microbiota

Outcome Measures

Primary Outcomes (3)

  • TMAO metabolite concentration change

    Plasma TMAO metabolite response

    Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours

  • TMAO metabolite concentration change

    Urinary TMAO metabolite response

    Urine: study baseline, pooled 6 hours study period

  • Gut microbiome profile

    16S rRNA

    Stool: one-time baseline

Secondary Outcomes (5)

  • One-carbon metabolite concentration change

    Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours

  • Phosphatidylcholine concentration change

    Blood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours

  • One-carbon metabolite concentration change

    Urine: study baseline, pooled 6 hours study period

  • Inflammation and cardiovascular disease risk marker concentration change

    Blood: study baseline to 6 hours

  • Flavin monooxygenase 3 (FMO3) 472 G>A genotype variant

    Blood: study baseline

Study Arms (3)

Water-soluble choline

EXPERIMENTAL

A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.

Other: Water-soluble choline

Fat-soluble choline

EXPERIMENTAL

A breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.

Other: Fat-soluble choline

No choline

ACTIVE COMPARATOR

A breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.

Other: No choline control

Interventions

600 mg choline as choline bitartrate

Water-soluble choline

600 mg choline as phosphatidylcholine

Fat-soluble choline

No choline

No choline

Eligibility Criteria

Age21 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men and women of any race or ethnicity
  • Age 21-50 y
  • BMI 20-24.9 kg/m2 or BMI 30-39.9 kg/m2

You may not qualify if:

  • Age \> 50 y
  • BMI outside of the normal-weight or obese range (BMI \< 20 kg/m2; BMI 25-29.9 kg/m2; or BMI \> or = 40 kg/m2)
  • Pregnant or planning to become pregnant during the course of the study; currently breastfeeding (females)
  • Vegetarians
  • Smokers or recreational drug users
  • Individuals with gastrointestinal diseases or complaints, chronic illnesses or other metabolic diseases (including trimethylaminuria)
  • Individuals who have taken antibiotics within the past 2 months
  • Individuals who are not willing to discontinue pre- and probiotics and dietary supplements for the time leading up to 2 months before the study and during the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Human Nutrition Studies Clinic, Utah State University

Logan, Utah, 84322, United States

Location

Related Publications (3)

  • Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400.

    PMID: 23614584BACKGROUND
  • Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.

    PMID: 21475195BACKGROUND
  • Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, Sutter JL, Caudill MA. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: A randomized controlled trial. Mol Nutr Food Res. 2017 Jan;61(1). doi: 10.1002/mnfr.201600324. Epub 2016 Aug 3.

    PMID: 27377678BACKGROUND

Study Officials

  • Clara E Cho, PhD

    Utah State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Randomized, controlled crossover design where participants consume 3 meals containing (i) free choline; (ii) phosphatidylcholine; or (iii) no choline in a random order separated by a 1-week washout period
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2020

First Posted

February 5, 2020

Study Start

November 9, 2017

Primary Completion

June 16, 2018

Study Completion

July 25, 2020

Last Updated

November 4, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations